AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38636950 — intervention group
Group type: EXPERIMENTAL
Intervention: TAF/FTC-based ART co-encapsulated with an ingestible sensor for 16 weeks
Number of subjects: 84
Study 38636983 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplanned extubation (UE)
Number of subjects: 2280
Study 38636983 — intervention group
Group type: COMPARATOR
Intervention: Planned extubation
Number of subjects: 2280
Study 38637128 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric fMRI (DWI, DCE, BOLD-MRI)
Number of subjects: 40
Study 38637135 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low energy diet (VLED) delivered by physiotherapists
Number of subjects: 88
Study 38637135 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 88
Study 38637212 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of measles vaccine and two or three doses of pneumococcal conjugate vaccine (PCV)
Number of subjects: 211
Study 38637212 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of metabolic markers (leptin, ghrelin, and adiponectin) and distribution of B-cell subsets
Number of subjects: 211
Study 38637212 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined effect of B-cell subsets, metabolic hormones, and nutritional status
Number of subjects: 211
Study 38637464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 0
Study 38637464 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study 38637464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38637495 — intervention group
Group type: EXPERIMENTAL
Intervention: sintilimab (200 mg per 3 weeks)
Number of subjects: 36
Study 38637498 — intervention group
Group type: EXPERIMENTAL
Intervention: Virus-specific T cell (VST) therapy targeting cytomegalovirus, Epstein-Barr virus, or adenovirus
Number of subjects: 77
Study 38637498 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids, graft-versus-host disease, transplant-associated thrombotic microangiopathy, and eculizumab treatment
Number of subjects: 77
Study 38637498 — intervention group
Group type: COMPARATOR
Intervention: Uptrending absolute lymphocyte and CD8 T cell counts
Number of subjects: 77
Study 38637744 — intervention group
Group type: EXPERIMENTAL
Intervention: Carer eSupport plus support as usual (SAU)
Number of subjects: 110
Study 38637744 — intervention group
Group type: COMPARATOR
Intervention: Support as usual (SAU) only
Number of subjects: 110
Study 38637754 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Number of subjects: 0
Study 38637754 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0
Study 38637755 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive registered nurse-based care (Quality Liver Nursing Care Model - QLiNCaM)
Number of subjects: 167
Study 38637755 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 167
Study 38637770 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate supplementation coupled with resistance training (Cr + RT)
Number of subjects: 200
Study 38637770 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) and resistance training (PLA + RT)
Number of subjects: 200
Study 38637772 — intervention group
Group type: EXPERIMENTAL
Intervention: External radiotherapy (≥45 Gy, 2-2.5 Gy per fraction) followed by anti-PD-1 immunotherapy (camrelizumab 200 mg once every 3 weeks)
Number of subjects: 36
Study 38637772 — intervention group
Group type: EXPERIMENTAL
Intervention: External radiotherapy plus camrelizumab
Number of subjects: 36
Study 38637829 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-II treatment in ACEi/ARB-unexposed patients
Number of subjects: 321
Study 38637829 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-II treatment in ACEi-exposed patients
Number of subjects: 321
Study 38637829 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-II treatment in ARB-exposed patients
Number of subjects: 321
Study 38638057 — intervention group
Group type: EXPERIMENTAL
Intervention: Half grafting of bovine bone mineral (DBBM-C) covered with non-resorbable dense polytetrafluoroethylene (dPTFE) membrane (Test 1 group)
Number of subjects: 56
Study 38638057 — intervention group
Group type: EXPERIMENTAL
Intervention: Half grafting of bovine bone mineral (DBBM-C) covered with collagen membrane (Test 2 group)
Number of subjects: 56
Study 38638057 — intervention group
Group type: COMPARATOR
Intervention: Full grafting with collagen membrane (DBBM-C + Collagen membrane) (Control group)
Number of subjects: 56
Study 38638180 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) and medical management
Number of subjects: 455
Study 38638180 — intervention group
Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 455
Study 38638324 — intervention group
Group type: EXPERIMENTAL
Intervention: DeepSurv architecture-based AI models (InceptionV3+ DeepSurv, InceptionResNetV2+ DeepSurv, ResNet50+ DeepSurv)
Number of subjects: 555
Study 38638324 — intervention group
Group type: EXPERIMENTAL
Intervention: Code-free AI application for pregnancy prediction
Number of subjects: 555
Study 38638398 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening program utilizing the Fracture Risk Assessment Tool (FRAX) for major osteoporotic fractures (MOF) followed by dual-energy x-ray absorptiometry (DXA) scan.
Number of subjects: 34129
Study 38638398 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who underwent DXA scans in the screening group.
Number of subjects: 34129
Study 38638398 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening).
Number of subjects: 34129
Study 38638399 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic metformin plus endocrine therapy (ET)
Number of subjects: 68
Study 38638400 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.2 mg
Number of subjects: 201
Study 38638400 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.1 mg
Number of subjects: 201
Study 38638400 — intervention group
Group type: COMPARATOR
Intervention: Laser therapy
Number of subjects: 201
Study 38638400 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular and systemic secondary outcomes
Number of subjects: 201
Study 38638400 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ocular outcomes
Number of subjects: 201
Study 38638673 — intervention group
Group type: EXPERIMENTAL
Intervention: Zilucoplan 0.3 mg/kg, self-administered subcutaneously, daily
Number of subjects: 200
Study 38638673 — intervention group
Group type: EXPERIMENTAL
Intervention: Zilucoplan 0.3 mg/kg
Number of subjects: 200
Study 38638839 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontact optical glucometer (NCGM)
Number of subjects: 0
Study 38638839 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38638854 — intervention group
Group type: EXPERIMENTAL
Intervention: High PD-L1 expression on immune cells
Number of subjects: 55
Study 38638854 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 55
Study 38638867 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg (n = 10)
Number of subjects: 22
Study 38638867 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 20 mg (n = 12)
Number of subjects: 22
Study 38639348 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of population- and sex-specific thresholds of troponins
Number of subjects: 0
Study 38639348 — intervention group
Group type: COMPARATOR
Intervention: Current uniform manufacturer-derived thresholds
Number of subjects: 0
Study 38639353 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 76
Study 38639353 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 76
Study 38639359 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with atrial fibrillation (AF)
Number of subjects: 10222
Study 38639433 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (20-120 mg/d) with lithium
Number of subjects: 0
Study 38639433 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (20-120 mg/d) with valproate
Number of subjects: 0
Study 38639433 — intervention group
Group type: COMPARATOR
Intervention: Lurasidone (20-120 mg/d) with lithium or valproate
Number of subjects: 0
Study 38639518 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical wound transcutaneous electrical nerve stimulation (SW-TENS)
Number of subjects: 120
Study 38639518 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar plexus and sciatic nerve transcutaneous electrical nerve stimulation (LS-TENS)
Number of subjects: 120
Study 38639518 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) with epidural fentanyl (Control group)
Number of subjects: 120
Study 38639542 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-Restricted Eating (TRE) - 10-hour eating window, 80% of calories before 1 p.m.
Number of subjects: 41
Study 38639542 — intervention group
Group type: COMPARATOR
Intervention: Usual Eating Pattern (UEP) - ≤16-hour window, ≥50% of calories after 5 p.m.
Number of subjects: 41
Study 38639697 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 293
Study 38639697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 293
Study 38639723 — intervention group
Group type: EXPERIMENTAL
Intervention: CPOE prompts (education, feedback, and real-time and risk-based CPOE prompts)
Number of subjects: 127403
Study 38639723 — intervention group
Group type: COMPARATOR
Intervention: Routine stewardship (control group)
Number of subjects: 127403
Study 38639729 — intervention group
Group type: EXPERIMENTAL
Intervention: CPOE stewardship bundle (education, feedback, and real-time MDRO risk-based CPOE prompts)
Number of subjects: 96451
Study 38639729 — intervention group
Group type: COMPARATOR
Intervention: Routine stewardship
Number of subjects: 96451
Study 38639763 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural enzymes mouthwash
Number of subjects: 49
Study 38639763 — intervention group
Group type: COMPARATOR
Intervention: Benzydamine mouthwash
Number of subjects: 49
Study 38639810 — intervention group
Group type: EXPERIMENTAL
Intervention: Young adults (18-39)
Number of subjects: 1590
Study 38639810 — intervention group
Group type: COMPARATOR
Intervention: Older adults (40-49)
Number of subjects: 1590
Study 38639810 — intervention group
Group type: COMPARATOR
Intervention: Older adults (50-64)
Number of subjects: 1590
Study 38639810 — intervention group
Group type: COMPARATOR
Intervention: Older adults (65+)
Number of subjects: 1590
Study 38639876 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand-alone intermittently scanned continuous glucose monitoring (isCGM)
Number of subjects: 159
Study 38639876 — intervention group
Group type: COMPARATOR
Intervention: Control group 1 (structured education programme and blood glucose monitoring)
Number of subjects: 159
Study 38639876 — intervention group
Group type: COMPARATOR
Intervention: Control group 2 (blood glucose monitoring only)
Number of subjects: 159
Study 38639888 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-a (leuprolide acetate) preoperatively
Number of subjects: 0
Study 38639888 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving GnRH-a)
Number of subjects: 0
Study 38639940 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered acupressure (SAA) with brief knee health education (KHE); practiced twice daily for 12 weeks.
Number of subjects: 314
Study 38639940 — intervention group
Group type: COMPARATOR
Intervention: KHE only (control group); received education about maintaining knee health on the same schedule and duration.
Number of subjects: 314
Study 38640017 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38640068 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA low dose (LD)
Number of subjects: 164
Study 38640068 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA high dose (HD)
Number of subjects: 164
Study 38640068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 38640123 — intervention group
Group type: EXPERIMENTAL
Intervention: Friends for Life Circles (FLC)
Number of subjects: 540
Study 38640123 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 540
Study 38640200 — intervention group
Group type: EXPERIMENTAL
Intervention: Etavopivat 400 mg once daily for 12 weeks (Open-label cohort)
Number of subjects: 36
Study 38640255 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad repertoire (BR) EBV-specific T cells (EBVSTs)
Number of subjects: 0
Study 38640255 — intervention group
Group type: COMPARATOR
Intervention: T2 antigen-specific EBVSTs
Number of subjects: 0
Study 38640327 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish version of the QoR-15 questionnaire (QoR-15T) administered preoperatively and 24 hours postoperatively
Number of subjects: 177
Study 38640327 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish version of the QoR-15 questionnaire (QoR-15T)
Number of subjects: 177
Study 38640348 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Number of subjects: 19
Study 38640453 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hemihepatectomy
Number of subjects: 352
Study 38640453 — intervention group
Group type: COMPARATOR
Intervention: Open hemihepatectomy
Number of subjects: 352
Study 38640500 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudendal nerve block (PNB) with 20 mL of 0.5% bupivacaine
Number of subjects: 44
Study 38640500 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 44
Study 38640500 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudendal nerve block (PNB)
Number of subjects: 44
Study 38640513 — intervention group
Group type: EXPERIMENTAL
Intervention: Clot removal with decompressive craniectomy (CR with DC)
Number of subjects: 204
Study 38640513 — intervention group
Group type: COMPARATOR
Intervention: Clot removal without decompressive craniectomy (CR)
Number of subjects: 204
Study 38640617 — intervention group
Group type: EXPERIMENTAL
Intervention: GATT-Patch
Number of subjects: 47
Study 38640622 — intervention group
Group type: EXPERIMENTAL
Intervention: SkillJoy EMI (savoring positive emotions)
Number of subjects: 85
Study 38640622 — intervention group
Group type: COMPARATOR
Intervention: Active control EMI (no savoring or positive emotion)
Number of subjects: 85
Study 38640748 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06939999 0.5 mg q.d. to 6 mg b.i.d. (part 1 dose escalation)
Number of subjects: 54
Study 38640748 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06939999 6 mg q.d. (part 2 dose expansion)
Number of subjects: 54
Study 38640885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue reactive (CR+) individuals
Number of subjects: 52
Study 38640885 — intervention group
Group type: COMPARATOR
Intervention: Cue non-reactive (CR-) individuals
Number of subjects: 52
Study 38640937 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 1610
Study 38640937 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 1610
Study 38640958 — intervention group
Group type: EXPERIMENTAL
Intervention: 3HP (weekly isoniazid plus rifapentine for 3 months)
Number of subjects: 128
Study 38640958 — intervention group
Group type: EXPERIMENTAL
Intervention: 9H (daily isoniazid for 9 months)
Number of subjects: 128
Study 38640958 — intervention group
Group type: COMPARATOR
Intervention: Control group (3HP or 9H without flu-like reactions)
Number of subjects: 128
Study 38640974 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured group psychoeducation (12 sessions)
Number of subjects: 154
Study 38640974 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 154
Study 38641023 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha2b for 48 weeks
Number of subjects: 55
Study 38641031 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate complete revascularization (CR) during primary angioplasty
Number of subjects: 0
Study 38641031 — intervention group
Group type: COMPARATOR
Intervention: In-hospital staged complete revascularization (CR)
Number of subjects: 0
Study 38641363 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping proton pump inhibitors (PPIs) for 1 and 2 weeks
Number of subjects: 15
Study 38641363 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidic bile salt solutions (ABS) treatment in Barrett's cells
Number of subjects: 15
Study 38641363 — intervention group
Group type: EXPERIMENTAL
Intervention: HIF-1α knockdown with siRNA or shRNA
Number of subjects: 15
Study 38641363 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of BO spheroids after ABS treatment
Number of subjects: 15
Study 38641570 — intervention group
Group type: EXPERIMENTAL
Intervention: Health and care services use during the lockdown period for people with dementia
Number of subjects: 10607
Study 38641570 — intervention group
Group type: EXPERIMENTAL
Intervention: Health and care services use during the lockdown period for those aged ≥ 80 years without dementia
Number of subjects: 10607
Study 38641570 — intervention group
Group type: EXPERIMENTAL
Intervention: Health and care services use during the lockdown period for all groups
Number of subjects: 10607
Study 38641570 — intervention group
Group type: EXPERIMENTAL
Intervention: Health and care services use after the lockdown period
Number of subjects: 10607
Study 38641570 — intervention group
Group type: EXPERIMENTAL
Intervention: GP contacts during the lockdown period
Number of subjects: 10607
Study 38641580 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence empowered decision support system for labeling anatomical organs using deep learning and clustering techniques.
Number of subjects: 0
Study 38641580 — intervention group
Group type: COMPARATOR
Intervention: Experienced sonographer (with more than 2000 performed scans).
Number of subjects: 0
Study 38641580 — intervention group
Group type: COMPARATOR
Intervention: Junior sonographer.
Number of subjects: 0
Study 38641716 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise program
Number of subjects: 52
Study 38641716 — intervention group
Group type: EXPERIMENTAL
Intervention: PROactive daily diary
Number of subjects: 52
Study 38641716 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable sensors
Number of subjects: 52
Study 38641716 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical assessments
Number of subjects: 52
Study 38641716 — intervention group
Group type: EXPERIMENTAL
Intervention: General patient experience
Number of subjects: 52
Study 38641716 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle strength and functional limitations
Number of subjects: 52
Study 38641768 — intervention group
Group type: EXPERIMENTAL
Intervention: L-PF-35 Dyspnea domain score
Number of subjects: 0
Study 38641773 — intervention group
Group type: EXPERIMENTAL
Intervention: SCRT (25 Gy in five fractions over 1 week) plus chemotherapy (4 cycles of CAPOX or 6 cycles of mFOLFOX) and Cadonilimab
Number of subjects: 50
Study 38641773 — intervention group
Group type: EXPERIMENTAL
Intervention: SCRT plus chemotherapy and Cadonilimab
Number of subjects: 50
Study 38641791 — intervention group
Group type: EXPERIMENTAL
Intervention: ZF2001 heterologous booster
Number of subjects: 240
Study 38641801 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate transfer to the ED
Number of subjects: 616
Study 38641801 — intervention group
Group type: COMPARATOR
Intervention: Appropriate transfer to the ED
Number of subjects: 616
Study 38641835 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning course 'Joint Prevention of Long-Term Ventilation' consisting of 7 modules
Number of subjects: 214
Study 38641835 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning course 'Joint Prevention of Long-Term Ventilation'
Number of subjects: 214
Study 38641998 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibeprenlimab (intravenous)
Number of subjects: 0
Study 38642204 — intervention group
Group type: COMPARATOR
Intervention: Strength training
Number of subjects: 386
Study 38642204 — intervention group
Group type: COMPARATOR
Intervention: Tai ji quan
Number of subjects: 386
Study 38642204 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching control
Number of subjects: 386
Study 38642238 — intervention group
Group type: EXPERIMENTAL
Intervention: emtricitabine/tenofovir disoproxil/rilpivirine (n=28)
Number of subjects: 40
Study 38642238 — intervention group
Group type: COMPARATOR
Intervention: emtricitabine/tenofovir disoproxil/efavirenz (n=12)
Number of subjects: 40
Study 38642245 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus endocrine therapy (ET) as first-line treatment
Number of subjects: 677
Study 38642245 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus endocrine therapy (ET) as second-line treatment
Number of subjects: 677
Study 38642245 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus endocrine therapy (ET)
Number of subjects: 677
Study 38642263 — intervention group
Group type: EXPERIMENTAL
Intervention: First lockdown
Number of subjects: 291
Study 38642263 — intervention group
Group type: EXPERIMENTAL
Intervention: Second lockdown
Number of subjects: 291
Study 38642263 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of checkups
Number of subjects: 291
Study 38642263 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous HbA1c value
Number of subjects: 291
Study 38642263 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational level (secondary vs tertiary)
Number of subjects: 291
Study 38642263 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational level (primary vs tertiary)
Number of subjects: 291
Study 38642263 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy score
Number of subjects: 291
Study 38642263 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-management score
Number of subjects: 291
Study 38642291 — intervention group
Group type: EXPERIMENTAL
Intervention: NeVa™ mechanical thrombectomy device (MTD)
Number of subjects: 15
Study 38642473 — intervention group
Group type: EXPERIMENTAL
Intervention: Early warm water sitz bath started 6 hours after surgery
Number of subjects: 64
Study 38642473 — intervention group
Group type: COMPARATOR
Intervention: Control group started warm water sitz bath on post-haemorrhoidectomy day 1
Number of subjects: 64
Study 38642472 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus Cabozantinib (NIVO + CABO)
Number of subjects: 651
Study 38642472 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (SUN)
Number of subjects: 651